Lydie Meheus obtained a PhD in Sciences at the University of Ghent (1986). She worked at Innogenetics (1987-2004) and as VP R&D at GENimmune (2005-2008), both Belgian biopharmaceutical companies. Lydie is the Managing Director of the Anticancer Fund (ACF), a Belgian Research Foundation of Public Utility dedicated to the development of cancer treatments regardless of their commercial value. Lydie co-founded the Anticancer Fund in 2013 with entrepreneur and major funder Luc Verelst. She is also the Executive Director of Reliable Cancer Therapies. In 2019, Lydie was appointed by the European Commission as alternate to represent patients for 3 years in the Committee for Advanced Therapies (CAT) one of the seven committees at the European Medicines Agency (EMA). She is also member of the Scientific and Clinical Advisory Board of OvaCure, a Danish non-profit organisation that supports research for breakthrough treatments in ovarian cancer. Lydie has published many international peer review manuscripts, lately on drug repurposing in cancer therapies. She is a breast cancer patient, diagnosed in 2018 and successfully treated since then.